Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193434 | 1.00 | HTR2C (0.45) | HTR2CACHEKDM1ATRPM8SLC6A2 | |
| SCHEMBL31250078 | 1.00 | HTR2C (0.45) | HTR2CACHEKDM1ATRPM8SLC6A2 | |
| SCHEMBL193872 | 1.00 | HTR2C (0.45) | HTR2CACHEKDM1ATRPM8SLC6A2 | |
| SCHEMBL30229855 | 1.00 | HTR2C (0.45) | HTR2CACHEKDM1ATRPM8SLC6A2 | |
| Hydrochloric Acid SCHEMBL11574629 | 0.98 | ACHE (0.47) | HTR2CACHEKDM1ATRPM8SLC6A2 | |
| Hydrochloric Acid SCHEMBL31186922 | 0.98 | ACHE (0.47) | HTR2CACHEKDM1ATRPM8SLC6A2 | |
| SCHEMBL1151017 | 0.89 | HTR2C (0.42) | HTR2CACHEKDM1ATRPM8SLC6A2 | |
| SCHEMBL29325494 | 0.87 | HTR2C (0.41) | HTR2CACHEKDM1ATRPM8SLC6A2 | |
| SCHEMBL18647394 | 0.84 | ACHE (0.40) | ACHEKDM1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11578773 | 0.80 | ACHE (0.38) | HTR2CACHESLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4096173-A | Chlorinated 1-aminoindane N-methyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 1978-06-20 | — | — | US | claimed |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| US-9751843-B2 | Substituted uracils and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-05 | — | — | US | disclosed |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20160297771-A1 | SUBSTITUTED URACILS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-10-13 | — | — | US | disclosed |
| CN-105980381-A | Substituted uracils and use thereof | 拜耳医药股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| EP-2402334-B1 | Inhibitors of E1 Activating Enzymes | MILLENNIUM PHARM INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | MILLENNIUM PHARM INC (US) | 2013-10-31 | — | — | US | disclosed |
| US-8487116-B2 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20070232686-A1 | Cyanoamidine P2X7 Antagonists for the Treatment of Pain | CARROLL WILLIAM A | 2007-10-04 | — | — | US | disclosed |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007092213-A2 | INHIBITORS OF E1 ACTIVATING ENZYME | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-7241776-B2 | Cyanoamidine P2X7 antagonists for the treatment of pain | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| WO-2007060121-A1 | INDANYL-AND TETRAHYDRONAPHTHYL-AMINO-AZOLINE COMPOUNDS FOR COMBATING ANIMAL PESTS | BASF SE (DE) | 2007-05-31 | — | — | WO | disclosed |
| EP-1658269-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060025614-A1 | Cyanoamidine P2X7 antagonists for the treatment of pain | ABBVIE INC. | 2006-02-02 | — | — | US | disclosed |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2004111009-A1 | FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2004-12-23 | — | — | WO | disclosed |
| US-4096173-A | Chlorinated 1-aminoindane N-methyl transferase inhibitors | ELI LILLY AND COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297771-A1 | SUBSTITUTED URACILS AND USE THEREOF | UNG, UMPS, TYMP | HTR2C 4059/4885ACHE 4197/4885KDM1A 3613/4885 |
| US-20170136024-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | HTR2C 4747/4885ACHE 30/4885KDM1A 513/4885 |
| US-20060025614-A1 | Cyanoamidine P2X7 antagonists for the treatment of pain | P2RX2, P2RX1, P2RX7 | HTR2C 139/4885ACHE 332/4885KDM1A 3553/4885 |
| US-20070232686-A1 | Cyanoamidine P2X7 Antagonists for the Treatment of Pain | P2RX2, P2RX1, P2RX7 | HTR2C 139/4885ACHE 332/4885KDM1A 3553/4885 |
| US-20190255052-A1 | Inhibitors of E1 Activating Enzymes | ECE1, RNASE1, RCE1 | HTR2C 4747/4885ACHE 30/4885KDM1A 513/4885 |
| US-20130165457-A9 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | HTR2C 4747/4885ACHE 30/4885KDM1A 513/4885 |
| US-20130289037-A1 | INHIBITORS OF E1 ACTIVTING ENZYMES | RNASE1, ECE1, CES1 | HTR2C 4799/4885ACHE 13/4885KDM1A 324/4885 |
| US-20050043351-A1 | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ARRB1, TRPV1, TRPV5 | HTR2C 564/4885ACHE 2141/4885KDM1A 2048/4885 |
| US-20070191293-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | HTR2C 4747/4885ACHE 30/4885KDM1A 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.